he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源邮箱
- 2022-04-26天麻有哪些功效 天麻除了镇静剂还有这些好处
- 2022-04-252013年国际抗癫痫联合会抗癫痫制剂使用指南
- 2022-04-25哮喘疾病的护理方法有哪些
- 孕妇能吃木瓜吗?
- 这三宝让肝脏重获年轻
- 「痛」悲伤:糖尿病神经痛药物治疗策略
- 20131026cctv10健康之路:王琦谈女性失眠的原因
- 医学观察栏:普华永道看涨体外诊断业务
- 直肠定植菌是活检后的感染源
- 私密┃同房后,用纸巾擦完?绝对不行。!
- 猛男必看 5壮阳法宝提升战斗力(2)
- 日常生活中如何护理附睾畸形?
- 争吵和压力会影响夫妻的生活!瑜伽或冥想可以缓解美国健康
- NICE推荐将Elmiron(戊糖多钠)治疗膀胱疼痛综合征
- Pancreatology: 过去糖尿病与急性胰腺炎的严重程度之间的关系
- 烟台胶东泌尿外科医院自治炎引起脓肿
- 首例新冠肺炎患者长期勃起异常
- 烧口综合征注意事项!
- JAMA Netw Open:中年步行速度与脑健康密切相关
- 女人过早对夫妻不利
- 布加氏综合征 布加氏综合征如何治疗?
- 囊痈容易与哪些疾病混淆
- 糖尿病小传教育一目了然
- 良性梗阻中绿色激光的应用趋势
- 什么时候是安全期?
- 不同类型的肾盂肾炎治疗 肾盂肾炎
- 灼烧综合征的原因不容忽视治疗
- 治疗类风湿性关节炎/膝骨关节炎的专家共识
- 福州一医院用嫩模照片宣传妇科被判赔偿3.2 万
- 【首发】织生科技完成首轮千万融资,重点创新脑神经认知障碍的临床诊疗和干预
- 小孩癫痫病怎么科学病人
- PM2.5危害极大 对付室外PM2.5专家有妙招
- 女性癫痫遗传吗 癫痫病人怎样化成健康宝宝
- 医疗地图 | 羊癫疯发作的危急关键时刻,你知道如何急救吗?
- 世界癫痫日 | 物理防治 规范诊疗 告别癫痫
- 癫痫病早期征状有哪些
- 癫痫病的常见病因都有什么
- CARS2:属于自己致痫基因
- 认真癫痫病需要多少钱
- 油煎刀鱼 香酥的美味药品
- 睡觉时突然颤动一下 新生儿睡觉颤动怎么办
- 癫痫病人能治好吗 癫痫病的疗程方法
- 人类记忆究竟如何形成及提取?迄今最清晰确凿证据出现!